Fossati Silvia, Ramos Cejudo Jaime, Debure Ludovic, Pirraglia Elizabeth, Sone Je Yeong, Li Yi, Chen Jingyun, Butler Tracy, Zetterberg Henrik, Blennow Kaj, de Leon Mony J
Department of Psychiatry, New York University, School of Medicine, New York, NY, USA.
Department of Neurology, New York University, School of Medicine, New York, NY, USA.
Alzheimers Dement (Amst). 2019 Jun 28;11:483-492. doi: 10.1016/j.dadm.2019.05.001. eCollection 2019 Dec.
Plasma tau may be an accessible biomarker for Alzheimer's disease (AD), but the correlation between plasma and cerebrospinal fluid (CSF) tau and the value of combining plasma tau with CSF tau and phospho-tau (P-tau) are still unclear.
Plasma-tau, CSF-tau, and P-tau were measured in 97 subjects, including elderly cognitively normal controls (n = 68) and patients with AD (n = 29) recruited at the NYU Center for Brain Health, with comprehensive neuropsychological and magnetic resonance imaging evaluations.
Plasma tau was higher in patients with AD than cognitively normal controls ( < .001, area under the receiver operating characteristic curve = 0.79) similarly to CSF tau and CSF P-tau and was negatively correlated with cognition in AD. Plasma and CSF tau measures were poorly correlated. Adding plasma tau to CSF tau or CSF P-tau significantly increased the areas under the receiver operating characteristic curve from 0.80 and 0.82 to 0.87 and 0.88, respectively.
Plasma tau is higher in AD independently from CSF-tau. Importantly, adding plasma tau to CSF tau or P-tau improves diagnostic accuracy, suggesting that plasma tau may represent a useful biomarker for AD, especially when added to CSF tau measures.
血浆tau蛋白可能是阿尔茨海默病（AD）一种可获取的生物标志物，但血浆与脑脊液（CSF）中tau蛋白之间的相关性以及将血浆tau蛋白与脑脊液tau蛋白和磷酸化tau蛋白（P-tau）联合使用的价值仍不清楚。
在纽约大学脑健康中心招募的97名受试者中测量了血浆tau蛋白、脑脊液tau蛋白和P-tau蛋白，这些受试者包括认知正常的老年对照组（n = 68）和AD患者（n = 29），并进行了全面的神经心理学和磁共振成像评估。
与脑脊液tau蛋白和脑脊液P-tau蛋白类似，AD患者的血浆tau蛋白高于认知正常对照组（P <.001，受试者操作特征曲线下面积 = 0.79），且与AD患者的认知呈负相关。血浆和脑脊液tau蛋白测量值之间的相关性较差。将血浆tau蛋白添加到脑脊液tau蛋白或脑脊液P-tau蛋白中，可使受试者操作特征曲线下面积分别从0.80和0.82显著增加到0.87和0.88。
AD患者的血浆tau蛋白水平较高，独立于脑脊液tau蛋白。重要的是，将血浆tau蛋白添加到脑脊液tau蛋白或P-tau蛋白中可提高诊断准确性，这表明血浆tau蛋白可能是AD的一种有用生物标志物，特别是当添加到脑脊液tau蛋白测量中时。
